Novacyt S.A. ("Novacyt", the "Company" or the “Group”): Half Year 2020 Results

PARIS & CAMBERLEY, England--(BUSINESS WIRE)--Regulatory News: Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited results for the six months ended 30 June 2020 and provides an update on its growth strategy. Summary highlights H1 2020 sales of €72.4 million and EBITDA of €49.4 million, resulting from the sale of the Company’s market leading PCR COVID-19 test, has transformed Novacyt Performance provides period end cash of €19.7m, fo